Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors

Kodaz,Hilmi; Hacibekiroglu,Ilhan; Erdogan,Bulent; Turkmen,Esma; Tozkir,Hilmi; Albayrak,Dogan; Uzunoglu,Sernaz; Cicin,Irfan

doi:10.3892/mco.2014.448

Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors

Authors:
- Hilmi Kodaz
- Ilhan Hacibekiroglu
- Bulent Erdogan
- Esma Turkmen
- Hilmi Tozkir
- Dogan Albayrak
- Sernaz Uzunoglu
- Irfan Cicin
View Affiliations

Affiliations: Department of Medical Oncology, Faculty of Medicine, Trakya University, Edirne 22030, Turkey, Department of Medical Genetics, Faculty of Medicine, Trakya University, Edirne 22030, Turkey, Department of Medical Surgery, Faculty of Medicine, Trakya University, Edirne 22030, Turkey
Published online on: October 27, 2014 https://doi.org/10.3892/mco.2014.448
Pages: 179-184

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the clinicopathological characteristics and distribution by tumor localization of KRAS point mutations in metastatic colorectal cancer. A total of 189 patients diagnosed with colorectal cancer between 2007 and 2014, who were either metastatic at the time of diagnosis or developed metastasis subsequently, were included in this study. KRAS mutation analysis was performed in the primary tumor tissues and KRAS mutations were identified in 47.6% of the patients. There was a high frequency of the p.G13D point mutation in left‑colon tumors (p=0.011), while the p.G12D point mutation was more frequent in right‑colon tumors (p=0.004). KRAS wild‑type frequency (p=0.02) was higher among patients aged <40 years. A comparison of codon 12 and 13 mutations revealed that codon 12 mutations were more common in the >50‑year‑old group (p=0.03) and codon 13 mutations were more common in the <70‑year‑old group (p=0.04). KRAS wild‑type tumors were localized in the right colon (p=0.005) and tumors with the p.G13D point mutation (p=0.018) were diagnosed at non‑metastatic stages. In conclusion, KRAS point mutations in colorectal cancer exhibited a heterogeneous distribution in terms of tumor localization. In addition, the p.G13D point mutation was found to differ from other mutations in several aspects.

View Figures

View References

1	Malvezzi M, Bertuccio P, Levi F, et al: European cancer mortality predictions for the year 2014. Ann Oncol. 25:1650–1656. 2014.PubMed/NCBI
2	Arrington AK, Heinrich EL, Lee W, et al: Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci. 13:12153–12168. 2012. View Article : Google Scholar : PubMed/NCBI
3	Almoguera C, Shibata D, Forrester K, et al: Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 53:549–554. 1988. View Article : Google Scholar : PubMed/NCBI
4	Kranenburg O: The KRAS oncogene: past, present, and future. Biochim Biophys Acta. 1756:81–82. 2005.PubMed/NCBI
5	De Roock W, Piessevaux H, De Schutter J, et al: KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 19:508–515. 2008.PubMed/NCBI
6	Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med. 319:525–532. 1988. View Article : Google Scholar : PubMed/NCBI
7	Bamford S, Dawson E, Forbes S, et al: The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer. 91:355–358. 2004.PubMed/NCBI
8	Piessevaux H, Buyse M, Schlichting M, et al: Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 31:3764–3775. 2013. View Article : Google Scholar : PubMed/NCBI
9	Brink M, Weijenberg MP, de Goeij AF, et al: Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study. Int J Cancer. 114:824–830. 2005. View Article : Google Scholar : PubMed/NCBI
10	Neumann J, Zeindl-Eberhart E, Kirchner T and Jung A: Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract. 205:858–862. 2009. View Article : Google Scholar : PubMed/NCBI
11	Andreyev HJ, Norman AR, Cunningham D, et al: Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 85:692–696. 2001.
12	Hamilton SR, Vogelstein B, Kudo S, et al: Carcinom. of the colon and rectum. World Health Organization classification of tumours. Pathology and genetics. Tumors of the digestive system. IARC Press; Lyon: pp. 103–119. 2000
13	Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008. View Article : Google Scholar : PubMed/NCBI
14	Brink M, de Goeij AF, Weijenberg MP, et al: K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis. 24:703–710. 2003. View Article : Google Scholar : PubMed/NCBI
15	Zahrani A, Kandil M, Badar T, et al: Clinico-pathological study of K-ras mutations in colorectal tumors in Saudi Arabia. Tumori. 100:75–79. 2014.PubMed/NCBI
16	Gil Ferreira C, Aran V, Zalcberg-Renault I, et al: KRAS mutations: variable incidences in a Brazilian cohort of 8,234 metastatic colorectal cancer patients. BMC Gastroenterol. 14(73)2014.PubMed/NCBI
17	Bleeker WA, Hayes VM, Karrenbeld A, et al: Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer. Am J Gastroenterol. 95:2953–2957. 2000.PubMed/NCBI
18	Zulhabri O, Rahman J, Ismail S, et al: Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer. Singapore Med J. 53:26–31. 2012.PubMed/NCBI
19	Minamoto T, Sawaguchi K, Mai M, et al: Infrequent K-ras activation in superficial-type (flat) colorectal adenomas and adenocarcinomas. Cancer Res. 54:2841–2844. 1994.PubMed/NCBI
20	Bazan V, Migliavacca M, Zanna I, et al: DNA ploidy and S-phase fraction, but not p53 or NM23-H1 expression, predict outcome in colorectal cancer patients. Result of a 5-year prospective study. J Cancer Res Clin Oncol. 128:650–658. 2002.PubMed/NCBI
21	Yamauchi M, Morikawa T, Kuchiba A, et al: Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut. 61:847–854. 2012. View Article : Google Scholar
22	Guerrero S, Casanova I, Farre L, et al: K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 60:6750–6756. 2000.
23	De Roock W, Jonker DJ, Di Nicolantonio F, et al: Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. Jama. 304:1812–1820. 2010.PubMed/NCBI